Zydus Cadila is likely to submit an application for emergency use authorisation of its Covid-19 vaccine candidate ZyCoV-D in two weeks.
Zydus Cadila will submit an application for emergency use authorisation of its Covid vaccine candidate in two weeks. (Photo: PTI file)
Ahmedabad-based pharmaceutical company Zydus Cadila is likely to submit an application for emergency use authorisation of its Covid-19 vaccine candidate ZyCoV-D to the Drug Controller General of India in two weeks.
Five crore doses of ZyCoV-D vaccine may be available by August or September.
Zydus Cadila is conducting trials of its vaccine candidate among the 0-18 year age group at present. Based on the trials, ZyCoV-D vaccine may be administered to children in India as well.
If approved, ZyCoV-D will be the fourth vaccine to be used in India's Covid-19 vaccination drive after Covishield, Covaxin and Sputnik V.
Earlier in April, Zydus Cadila announced that its drug Virafin had received restricted emergency use approval from the Drug Controller General of India for the treatment of mild cases of Covid-19.
Zydus Cadila's Covid-19 vaccine candidate is India's first indigenously developed DNA vaccine candidate. It is to be administered via intradermal injection. It is easy to administer, according to the developers.
It has to be stored between 2 and 8 degrees Celsius but remains stable even at room temperature conditions at 25 degrees Celsius.
Click here for IndiaToday.in’s complete coverage of the coronavirus pandemic.